阿福他酶α有哪几个版本?分别多少钱?

Afotalase α is an enzyme replacement therapy drug for hypophosphatasia (HPP), developed by Alexion Pharmaceuticals of the United States, with the trade name Strensiq. Currently, there are only original versions of the drug on the market, and no generic drugs have yet been launched. The drug is available in various strengths, including 18mg/0.45mL, 28mg/0.7mL, 40mg/mL and 80mg/0.8mL, among which the price of 18mg/0.45mL is approximately US$13,210. Afotalase α has been approved in many countries such as Europe and the United States, and clinical data shows that it can significantly increase patient survival rates and improve bone development. This article will introduce the drug in detail from three aspects: version classification, price information and efficacy.

What versions of aftase alpha are there?

Currently, it is only produced by Ruisong Pharmaceuticals in the United States, and there are no generics or biosimilars. The drug is sold globally under the trade name Strensiq and is an originator drug.

Original drug version

The original drug of aftase α was developed by Ruisong Pharmaceuticals (now a subsidiary of AstraZeneca). It was approved for marketing in the United States in 2015, and was subsequently approved in Europe, Japan and other regions. This drug is currently the only enzyme replacement therapy approved in the world for the treatment of hypophosphatasia.

Current status of generic drugs

As of July 2025, there are no generic drugs of aftase alfa on the market globally. Since the drug is a biological agent and the production process is complex, it is difficult to produce a generic version in the short term.

The original drug version of aftase alfa is widely used around the world, but due to its high price, many patients still look forward to more economical alternatives in the future.

How much do different versions of aftase α cost?

The price of aftase α varies depending on the specifications, and it has not yet been officially approved for marketing in China. Patients need to purchase it through overseas channels.

Price of 18mg/0.45mL specifications

The price of 18mg/0.45mL/box of aftase alpha is approximately US$13,205. It is suitable for adult standard dose treatment and requires 2-3 boxes per month.

Price of other specifications

Afotalase α is also available in 28mg/0.7mL, 40mg/mL and 80mg/0.8mL. The price varies depending on the specifications. The 80mg/0.8mL specification is suitable for patients with larger body weight, but is prohibited for patients weighing less than 40kg.

The high price of aftase alpha limits its widespread application worldwide, and patients are looking forward to more economical alternative treatment options in the future.

The efficacy of afotalase α

As the world’s first enzyme replacement therapy for hypophosphatasia, the clinical efficacy of afotalase α has been confirmed by multiple studies.

Significantly improve survival rate

Clinical data show that the 1-year survival rate of perinatal/infancy patients treated with aftase α is higher, and the 5-year survival rate is higher than that of the control group, with significant differences in efficacy.

Improve bone and respiratory function

This drug can reverse insufficient bone mineralization, promote an increase in bone density, and reduce the risk of fractures. At the same time, it can improve the symptoms of respiratory muscle weakness and reduce the incidence of respiratory failure in infants and young children.

Afotalase alfa brings a revolutionary treatment option to patients with hypophosphatasia, and its efficacy has changed the natural history of the disease.